Silvercrest Asset Management’s NovoCure NVCR Stock Holding History

Silvercrest Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.55M	Buy	784,805 +77,196	+11%	+$964K	0.06%	335
2025 Q4	$9.15M	Buy	707,609 +1,534	+0.2%	+$19.7K	0.06%	332
2025 Q3	$9.12M	Buy	706,075 +165,778	+31%	+$2.21M	0.06%	333
2025 Q2	$9.62M	Buy	540,297 +82,269	+18%	+$1.43M	0.06%	322
2025 Q1	$8.16M	Buy	458,028 +109,721	+32%	+$2.49M	0.06%	330
2024 Q4	$10.4M	Sell	348,307 -147,804	-30%	-$3.13M	0.07%	292
2024 Q3	$7.75M	Buy	496,111 +110,701	+29%	+$2.01M	0.05%	307
2024 Q2	$6.6M	Buy	+385,410	New	+$6.78M	0.05%	352
2021 Q1	–	Sell	-1,384	Closed	-$239K	–	865
2020 Q4	$239K	Sell	1,384 -1,787	-56%	-$245K	﹤0.01%	751
2020 Q3	$353K	Buy	+3,171	New	+$254K	﹤0.01%	648

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Silvercrest Asset Management's NVCR Position: Q1 2026 in Review

Silvercrest Asset Management increased its NovoCure (NVCR) stake by 11% in Q1 2026, buying an estimated $964K and bringing the position to 784,805 shares worth $8.55M. The position accounts for 0.06% of the portfolio, ranked #335.

Silvercrest Asset Management first reported a position in NVCR in Q3 2020 and has held it in 10 quarters since. The position peaked at $10.4M in Q4 2024. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Silvercrest Asset Management held 784,805 shares of NovoCure worth $8.55M as of Q1 2026.
Silvercrest Asset Management bought 77,196 NovoCure shares in Q1 2026, an estimated $964K.
NovoCure made up 0.06% of Silvercrest Asset Management's portfolio in Q1 2026, its #335 holding.
Silvercrest Asset Management first reported a position in NovoCure in Q3 2020 and has held it in 10 quarters since.
Silvercrest Asset Management's NovoCure position peaked at $10.4M in Q4 2024.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.